login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SELLAS LIFE SCIENCES GROUP I (SLS) Stock News
USA
-
Nasdaq
- NASDAQ:SLS -
US81642T2096
-
Common Stock
1.5288
USD
-0.02 (-1.37%)
Last: 11/25/2025, 10:05:01 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SLS Latest News, Press Relases and Analysis
All
Press Releases
14 days ago - By: Benzinga
- Mentions:
TEVA
EW
LLY
MDT
...
10 Health Care Stocks With Whale Alerts In Today's Session
14 days ago - By: Benzinga
- Mentions:
PZZA
Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News
a month ago - By: Stocktwits
- Mentions:
IWO
URTY
Why Is SELLAS Life Sciences Stock Falling Today?
a month ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
a month ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
a month ago - By: Stocktwits
Sellas Life Sciences Stock Jumps Over 7% Premarket: Buzz Builds Ahead Of Weekend Cancer Drug Presentation In Berlin
a month ago - By: Stocktwits
- Mentions:
IWMW
VTWG
SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment
a month ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
2 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
2 months ago - By: Stocktwits
- Mentions:
IWMW
VTWG
Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants
3 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
3 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
4 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
4 months ago - By: Zacks Investment Research
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
4 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
5 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
5 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
6 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
6 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
6 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
6 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
7 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
7 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
7 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
8 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
8 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
9 months ago - By: SELLAS Life Sciences Group, Inc.
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Please enable JavaScript to continue using this application.